



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/811,725	03/29/2004	Sateesh Apte	14705	1415
28061	7590	05/31/2007	EXAMINER	
THEODORE J. BIELEN JR.			PARKIN, JEFFREY S	
BIELEN, LAMPE, & THOEMING			ART UNIT	PAPER NUMBER
1390 WILLOW PASS ROAD				1648
SUITE 1020				
CONCORD, CA 94520				
		MAIL DATE	DELIVERY MODE	
		05/31/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)	
	10/811,725	APTE, SATEESH	

Examiner
Jeffrey S. Parkin, Ph.D.

Art Unit

1648

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 03 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 28 February 2007.

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-6 is/are pending in the application.

4a) Of the above claim(s) 4-6 is/are withdrawn from consideration.

5) Claim(s) 1 is/are allowed.

6) Claim(s) 3 is/are rejected.

7) Claim(s) 2 is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____.

4) Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.
5) Notice of Informal Patent Application
6) Other: _____.

Serial No.: 10/811,725
Applicant: Apte, S.

Docket No.: 14705
Filing Date: 03/29/2004

Detailed Office Action

Status of the Claims

Acknowledgement is hereby made of receipt and entry of the communication filed 28 February, 2007. Applicant's election of Group I (claims 1-3) with traverse is acknowledged. However, because applicant did not distinctly and specifically point out the purported errors in the restriction requirement, the election has been treated as an election without traverse (refer to M.P.E.P. § 818.03(a)). Claims 4-6 are withdrawn from further consideration by the examiner, pursuant to 37 C.F.R. § 1.142(b), as being drawn to a non-elected invention.

35 U.S.C. § 120

Applicants are reminded that if the benefit of a prior-filed application under 35 U.S.C. § 120 is desired, a specific reference to the prior-filed application in compliance with 37 C.F.R. § 1.78(a) must be included in the first sentence(s) of the specification following the title or in an application data sheet. For benefit claims under 35 U.S.C. 120, 121 or 365(c), the reference must include the relationship (i.e., continuation, divisional, or continuation-in-part) of the applications. Applicants are advised that the status of U.S. Serial No. 08/879,099, has changed. This application has matured into U.S. Patent No. 6,713,064. Appropriate amendment is required.

37 C.F.R. § 1.98

Applicants are reminded that the listing of references in the specification is not a proper information disclosure statement. 37 C.F.R. § 1.98(b) requires a list of all patents,

publications, applications, or other information submitted for consideration by the Office, and M.P.E.P. § 609.04(a), subsection I. states, "the list may not be incorporated into the specification but must be submitted in a separate paper." Therefore, unless the references have been cited by the examiner on form PTO-892, they have not been considered.

Claim Objections

Claim 2 is objected to because of the following informality: the term "burdens" should read -burden-. Appropriate correction is required.

35 U.S.C. § 112, First Paragraph

The following is a quotation of the first paragraph of 35 U.S.C. § 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Enablement

Claim 3 is rejected under 35 U.S.C. § 112, first paragraph, as failing to comply with the enablement requirement. The claim contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The claim is directed toward a therapeutic suspension comprising Nef-deficient viral particles, wherein said particles are capable of restoring

normal cytotoxic T-cell (CTL) activation pathways. The legal considerations that govern enablement determinations pertaining to undue experimentation have been clearly set forth. *Enzo Biochem, Inc.*, 52 U.S.P.Q.2d 1129 (C.A.F.C. 1999). *In re Wands*, 8 U.S.P.Q.2d 1400 (C.A.F.C. 1988). *Ex parte Forman* 230 U.S.P.Q. 546 (PTO Bd. Pat. App. Int., 1986). The courts concluded that several factual inquiries should be considered when making such assessments including the quantity of experimentation necessary, the amount of direction or guidance presented, the presence or absence of working examples, the nature of the invention, the state of the prior art, the relative skill of those in that art, the predictability or unpredictability of the art and the breadth of the claims. *In re Rainer*, 52 C.C.P.A. 1593, 347 F.2d 574, 146 U.S.P.Q. 218 (1965). The disclosure fails to provide adequate guidance pertaining to a number of these considerations as follows:

Amount of Direction/Guidance Provided

The disclosure fails to provide any guidance pertaining to the role of Nef-deficient viruses in restoring CTL activation pathways. There is no discussion of the immunopathogenesis of HIV-1 infection and what leads to CTL dysfunction. The specification fails to shed any illumination on the topic.

Working Embodiments

The disclosure fails to provide any working embodiments. It is noted that the claimed composition was administered to patients in a double-blinded placebo-controlled study. These patients displayed increased CD4+ counts and reductions in viral load. However, none of the examples set forth in the specification measured any parameters related to CTL activation.

State-of-the-Art

The state-of-the-art concerning HIV-1 vaccine development is one of unpredictability. Numerous attempts are restoring lymphocyte functions through vaccine administration have failed. This is due to several factors including a lack of understanding of the human correlates of protection, the down-regulation of MHC class I molecules, the quasispecies nature of HIV infection which leads to rapid immune escape and evasion, and the lack of adequate animal models that are capable of predicting clinical efficacy (Piguet and Trono, 2001; Mooj and Heeney, 2001; Barouch and Letvin, 2002; Letvin and Walker, 2003; Altman and Feinberg, 2004; Gallo, 2005; Betts, 2005). Additional mechanisms contributing to the overall CTL immune impairment noted in HIV-infected patients is the presence of defective CTLs that are not capable of differentiating, CTLs that are deficient in cytokine production; the downmodulation of key T-cell activation signaling pathways, and the inability of CTLs to proliferate in response to antigenic challenge. The last item is particularly interesting, since it suggests the administration of a vaccine cannot overcome the immune dysfunction associated with HIV infection. The claimed invention necessitates the restoration of CTL activation signals. However, to date, no CTL vaccine has been effective at restoring normal cellular functions.

Therefore, when all the aforementioned factors are considered *in toto*, it would clearly require undue experimentation from the skilled artisan to practice the claimed invention.

Allowable Subject Matter

Claim 1 appears to be free of the prior art and is allowable.


Correspondence

Any inquiry concerning this communication should be directed to Jeffrey S. Parkin, Ph.D., whose telephone number is (571) 272-0908. The examiner can normally be reached Monday through Thursday from 10:30 AM to 9:00 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Bruce R. Campell, Ph.D., can be reached at (571) 272-0974. Direct general status inquiries to the Technology Center 1600 receptionist at (571) 272-1600. Informal communications may be submitted to the Examiner's RightFAX account at (571) 273-0908.

Applicants are reminded that the United States Patent and Trademark Office (Office) requires most patent related correspondence to be: a) faxed to the Central FAX number (571-273-8300) (updated as of July 15, 2005), b) hand carried or delivered to the Customer Service Window (now located at the Randolph Building, 401 Dulany Street, Alexandria, VA 22314), c) mailed to the mailing address set forth in 37 C.F.R. § 1.1 (e.g., P.O. Box 1450, Alexandria, VA 22313-1450), or d) transmitted to the Office using the Office's Electronic Filing System. This notice replaces all prior Office notices specifying a specific fax number or hand carry address for certain patent related correspondence. For further information refer to the Updated Notice of Centralized Delivery and Facsimile Transmission Policy for Patent Related Correspondence, and Exceptions Thereto, 1292 Off. Gaz. Pat. Office 186 (March 29, 2005).

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Respectfully,


Jeffrey S. Parkin, Ph.D.
Primary Examiner
Art Unit 1648

29 May, 2007